DE60027870D1 - Genetische manipulierte herpesviren zur behandlung von tumoren - Google Patents

Genetische manipulierte herpesviren zur behandlung von tumoren

Info

Publication number
DE60027870D1
DE60027870D1 DE60027870T DE60027870T DE60027870D1 DE 60027870 D1 DE60027870 D1 DE 60027870D1 DE 60027870 T DE60027870 T DE 60027870T DE 60027870 T DE60027870 T DE 60027870T DE 60027870 D1 DE60027870 D1 DE 60027870D1
Authority
DE
Germany
Prior art keywords
herpesvirus
tumors
treatment
manipulated
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027870T
Other languages
English (en)
Other versions
DE60027870T2 (de
Inventor
Ralph Weichselbaum
Bernard Roizman
Richard Whitley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
UAB Research Foundation
Original Assignee
Arch Development Corp
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp, UAB Research Foundation filed Critical Arch Development Corp
Publication of DE60027870D1 publication Critical patent/DE60027870D1/de
Application granted granted Critical
Publication of DE60027870T2 publication Critical patent/DE60027870T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
DE60027870T 1999-02-05 2000-02-04 Genetische manipulierte herpesviren zur behandlung von tumoren Expired - Lifetime DE60027870T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24474899A 1999-02-05 1999-02-05
US244748 1999-02-05
PCT/US2000/002814 WO2000045853A2 (en) 1999-02-05 2000-02-04 Treatment of tumors with genetically engineered herpes virus

Publications (2)

Publication Number Publication Date
DE60027870D1 true DE60027870D1 (de) 2006-06-14
DE60027870T2 DE60027870T2 (de) 2006-12-28

Family

ID=22923971

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60039730T Expired - Lifetime DE60039730D1 (de) 1999-02-05 2000-02-04 Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
DE60027870T Expired - Lifetime DE60027870T2 (de) 1999-02-05 2000-02-04 Genetische manipulierte herpesviren zur behandlung von tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60039730T Expired - Lifetime DE60039730D1 (de) 1999-02-05 2000-02-04 Genetisch manipulierte Herpesviren zur Behandlung von Tumoren

Country Status (10)

Country Link
US (3) US20030207829A9 (de)
EP (2) EP1150696B1 (de)
JP (1) JP4623832B2 (de)
AT (2) ATE402713T1 (de)
AU (2) AU772471B2 (de)
CA (1) CA2361892C (de)
DE (2) DE60039730D1 (de)
DK (1) DK1695714T3 (de)
ES (2) ES2310382T3 (de)
WO (1) WO2000045853A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1390046A4 (de) 1999-04-15 2005-04-20 Wellstat Biologics Corp Behandlung von neoplasmen mit viren
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2003282691A1 (en) 2002-10-07 2004-05-04 University Of Chicago Targeting of herpes simplex virus to specific receptors
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
CA2687301C (en) * 2007-05-09 2016-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
US8703120B2 (en) * 2008-05-29 2014-04-22 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
AU2016277149A1 (en) * 2015-06-11 2018-02-01 University Of Miami Cancer treatment and diagnosis
AU2016403583B2 (en) 2016-04-22 2020-05-28 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
KR101974169B1 (ko) * 2018-08-10 2019-04-30 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스 및 이의 제조방법
KR20220041884A (ko) * 2019-08-16 2022-04-01 임비라 컴퍼니 리미티드 전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) * 1986-04-29 1991-03-12 Novagene, Inc. Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death
US5593879A (en) * 1993-01-15 1997-01-14 Massachusetts Institute Of Technology Cell death genes of Drosophila melanogaster and vertebrate analogs
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
WO1997026904A1 (en) * 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
CA2200633A1 (en) * 1997-03-21 1998-09-21 Yuman Fong Rapid production of autologous tumor vaccines

Also Published As

Publication number Publication date
JP2002536347A (ja) 2002-10-29
ES2263454T3 (es) 2006-12-16
US20110002890A1 (en) 2011-01-06
WO2000045853A2 (en) 2000-08-10
CA2361892C (en) 2010-05-25
DK1695714T3 (da) 2008-11-10
US20030207829A9 (en) 2003-11-06
AU2980000A (en) 2000-08-25
US8318691B2 (en) 2012-11-27
EP1150696B1 (de) 2006-05-10
ATE402713T1 (de) 2008-08-15
AU2004203458B2 (en) 2007-05-17
DE60039730D1 (de) 2008-09-11
US8772261B2 (en) 2014-07-08
AU772471B2 (en) 2004-04-29
US20020019362A1 (en) 2002-02-14
CA2361892A1 (en) 2000-08-10
AU2004203458A1 (en) 2004-08-26
ATE325615T1 (de) 2006-06-15
ES2310382T3 (es) 2009-01-01
EP1695714A1 (de) 2006-08-30
JP4623832B2 (ja) 2011-02-02
US20130039890A1 (en) 2013-02-14
DE60027870T2 (de) 2006-12-28
EP1150696A2 (de) 2001-11-07
EP1695714B1 (de) 2008-07-30
WO2000045853A3 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DE69840006D1 (de) Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von multiplen Myelom
HK1028935A1 (en) Treatment of neoplasms with interferon-sernsitive,clonal viruses
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DE69612649T2 (de) Indolinonverbindungen zur behandlung von krankheiten
FI971568A (fi) Menetelmä resistenttien kasvainten hoitamiseksi
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
HK1063427A1 (en) Anti-ngf antibodies for the treatment of various disorders
ATE423598T1 (de) Lichtquelle zur photodynamischen therapie
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
ATE241994T1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
MXPA02001204A (es) Compuestos calciliticos.
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition